Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Invested Capital (2016 - 2025)

IGC Pharma has reported Invested Capital over the past 15 years, most recently at $8.1 million for Q3 2025.

  • Quarterly Invested Capital rose 9.69% to $8.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Sep 2025, up 9.69% year-over-year, with the annual reading at $6.3 million for FY2025, 13.54% down from the prior year.
  • Invested Capital was $8.1 million for Q3 2025 at IGC Pharma, up from $6.1 million in the prior quarter.
  • Over five years, Invested Capital peaked at $33.1 million in Q1 2021 and troughed at $6.1 million in Q2 2025.
  • The 5-year median for Invested Capital is $14.1 million (2023), against an average of $16.3 million.
  • Year-over-year, Invested Capital surged 35.69% in 2021 and then crashed 50.9% in 2024.
  • A 5-year view of Invested Capital shows it stood at $29.5 million in 2021, then tumbled by 37.86% to $18.3 million in 2022, then tumbled by 50.58% to $9.1 million in 2023, then tumbled by 30.86% to $6.3 million in 2024, then increased by 29.29% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Invested Capital are $8.1 million (Q3 2025), $6.1 million (Q2 2025), and $6.3 million (Q1 2025).